HK1033838A1 - Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination - Google Patents

Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination

Info

Publication number
HK1033838A1
HK1033838A1 HK01103307A HK01103307A HK1033838A1 HK 1033838 A1 HK1033838 A1 HK 1033838A1 HK 01103307 A HK01103307 A HK 01103307A HK 01103307 A HK01103307 A HK 01103307A HK 1033838 A1 HK1033838 A1 HK 1033838A1
Authority
HK
Hong Kong
Prior art keywords
ofcompositions
asociated
vaccination
tumor
preparation
Prior art date
Application number
HK01103307A
Other languages
English (en)
Inventor
Teresa Cabezon Silva
Joseph Cohen
Moncef Mohamed Slaoui
Carlota Vinals Bassols
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Priority to HK06101448.0A priority Critical patent/HK1083026A1/xx
Publication of HK1033838A1 publication Critical patent/HK1033838A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK01103307A 1998-02-05 2001-05-11 Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination HK1033838A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine
PCT/EP1999/000660 WO1999040188A2 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations

Publications (1)

Publication Number Publication Date
HK1033838A1 true HK1033838A1 (en) 2001-09-28

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
HK06111055.3A HK1093522A1 (en) 1998-02-05 2001-05-11 A process for the purification or production of a mage protein
HK01103307A HK1033838A1 (en) 1998-02-05 2001-05-11 Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination
HK06111054.4A HK1093521A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK06111055.3A HK1093522A1 (en) 1998-02-05 2001-05-11 A process for the purification or production of a mage protein

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK06111054.4A HK1093521A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination

Country Status (26)

Country Link
US (3) US8097257B2 (hu)
EP (4) EP1659179B1 (hu)
JP (2) JP4768121B2 (hu)
KR (2) KR100633212B1 (hu)
CN (1) CN1227360C (hu)
AR (1) AR018064A1 (hu)
AT (4) ATE505542T1 (hu)
AU (1) AU737337B2 (hu)
BR (1) BR9907691B1 (hu)
CA (2) CA2319309C (hu)
CY (4) CY1105685T1 (hu)
CZ (2) CZ298364B6 (hu)
DE (3) DE69943359D1 (hu)
DK (4) DK1053325T3 (hu)
ES (2) ES2342416T3 (hu)
HK (4) HK1093522A1 (hu)
HU (1) HU228467B1 (hu)
IL (4) IL137442A0 (hu)
NO (2) NO328507B1 (hu)
NZ (1) NZ506086A (hu)
PT (4) PT1659179E (hu)
SA (1) SA99200126B1 (hu)
SI (4) SI1053325T1 (hu)
TR (1) TR200002284T2 (hu)
TW (1) TWI238853B (hu)
WO (1) WO1999040188A2 (hu)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768121B2 (ja) 1998-02-05 2011-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
ID28387A (id) * 1998-10-05 2001-05-17 M & E Biotech As Metoda baru untuk vaksinasi terapeutik
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
DK1650221T3 (da) * 2000-02-23 2012-09-03 Glaxosmithkline Biolog Sa Nye forbindelser
DE60134499D1 (de) * 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
AU5810201A (en) * 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US6846883B2 (en) * 2000-06-05 2005-01-25 The Brigham And Women's Hospital, Inc. Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
ES2374620T3 (es) 2000-06-20 2012-02-20 Corixa Corporation Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
CN100548373C (zh) * 2000-10-18 2009-10-14 葛兰素史密丝克莱恩生物有限公司 疫苗
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US8921534B2 (en) 2001-12-12 2014-12-30 Sanofi Pasteur Limited Enhancement of the immune response using CD36-binding domain
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
WO2005021588A1 (en) * 2003-08-29 2005-03-10 The Nottingham Trent University Gastric and prostate cancer associated antigens
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP2392348A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
ATE515566T1 (de) * 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1951891B1 (en) * 2005-11-14 2012-02-15 Université Laval Cancer antigen mage-a9 and uses thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) * 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
PE20080742A1 (es) 2006-06-02 2008-08-06 Glaxosmithkline Biolog Sa Perfil genico y procedimiento de identificacion
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2486938T1 (sl) 2006-09-26 2018-09-28 Infectious Disease Research Institute Sestavek cepiva, ki vsebuje sintetični adjuvans
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
BRPI0806463A2 (pt) * 2007-01-15 2011-09-06 Glaxosmithkline Biolog Sa proteìna de fusão, seqüência de ácido nucleico, vetor, célula hospedeira, vacina, uso de uma proteìna ou ácido nucleico ou vetores, processo para a produção de uma proteìna de fusão, e, método para tratar um paciente que sofre de cáncer
WO2009046858A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of kisspeptin 13 and compositions thereof
WO2009033680A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
EA017879B1 (ru) 2007-09-17 2013-03-29 Онкометилом Сайенсиз Са Улучшенное определение экспрессии mage-a
PL2200642T3 (pl) * 2007-10-19 2012-09-28 Novartis Ag Preparaty szczepionek meningokokowych
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
WO2010136443A1 (en) 2009-05-27 2010-12-02 Glaxosmithkline Biologicals S.A. Casb7439 constructs
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
JP6010463B2 (ja) 2010-01-27 2016-10-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変された結核抗原
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013020875A2 (pt) 2011-02-15 2019-09-24 Immune Design Corp método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
JP2015503503A (ja) * 2011-12-22 2015-02-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｂｒａｆ阻害剤および／またはｍｅｋ阻害剤とともにｍａｇｅａ３免疫療法薬を用いた癌の治療方法
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
SG11201506727RA (en) 2013-03-01 2015-09-29 Astex Pharmaceuticals Inc Drug combinations
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
CN109312402A (zh) 2016-04-11 2019-02-05 得克萨斯州大学系统董事会 用于检测单个t细胞受体亲和力和序列的方法和组合物
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
AU2019386830A1 (en) 2018-11-29 2021-06-24 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022136952A1 (en) 2020-12-23 2022-06-30 Infectious Disease Research Institute Solanesol vaccine adjuvants and methods of preparing same
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001716A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Protease resistant pdgf and methods of use
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
DK0676964T3 (da) 1991-11-14 2001-02-05 Brigham & Womens Hospital Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
GB9213559D0 (en) 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69524264T2 (de) 1994-03-01 2002-07-18 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
CA2201327A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11508767A (ja) 1995-06-29 1999-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ マウス腫瘍拒絶抗原前駆体ｓｍａｇｅ−３をコードする単離核酸分子
WO1997013858A2 (en) 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
EP0941366A2 (en) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelic markers
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP4768121B2 (ja) 1998-02-05 2011-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
WO1999053095A2 (en) 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
EP1659179B1 (en) 2011-06-15
BR9907691B1 (pt) 2011-05-31
EP1659178A2 (en) 2006-05-24
DE69929310D1 (de) 2006-03-30
DE69943359D1 (de) 2011-05-26
PT1053325E (pt) 2006-05-31
DK1659178T3 (da) 2010-07-12
US20100209444A1 (en) 2010-08-19
NZ506086A (en) 2003-01-31
EP1053325B1 (en) 2006-01-04
KR100824105B1 (ko) 2008-04-21
BR9907691A (pt) 2000-11-14
EP1659178B1 (en) 2010-03-31
CA2584482C (en) 2012-03-27
DK1053325T3 (da) 2006-05-22
CA2319309A1 (en) 1999-08-12
NO20003958L (no) 2000-10-04
IL137442A0 (en) 2001-07-24
US20120269835A1 (en) 2012-10-25
CZ298347B6 (cs) 2007-09-05
WO1999040188A2 (en) 1999-08-12
ATE513042T1 (de) 2011-07-15
CA2584482A1 (en) 1999-08-12
PT1659178E (pt) 2010-06-28
EP1053325A2 (en) 2000-11-22
IL188875A0 (en) 2009-02-11
ATE505542T1 (de) 2011-04-15
SI1659178T1 (sl) 2010-07-30
CY1111831T1 (el) 2015-10-07
HK1093522A1 (en) 2007-03-02
HK1083026A1 (en) 2006-06-23
US8044183B2 (en) 2011-10-25
HUP0102639A3 (en) 2004-04-28
KR100633212B1 (ko) 2006-10-11
SA99200126B1 (ar) 2006-08-20
AR018064A1 (es) 2001-10-31
PL342852A1 (en) 2001-07-16
CN1227360C (zh) 2005-11-16
TR200002284T2 (tr) 2000-11-21
KR20010040675A (ko) 2001-05-15
TWI238853B (en) 2005-09-01
ATE315088T1 (de) 2006-02-15
CY1111672T1 (el) 2015-10-07
IL188875A (en) 2011-08-31
AU2722099A (en) 1999-08-23
IL179010A0 (en) 2007-03-08
JP2009201510A (ja) 2009-09-10
DK1659179T3 (da) 2011-10-10
NO20091665L (no) 2000-10-04
JP2002502604A (ja) 2002-01-29
US20100204458A1 (en) 2010-08-12
ATE462788T1 (de) 2010-04-15
KR20060067977A (ko) 2006-06-20
AU737337B2 (en) 2001-08-16
CY1110180T1 (el) 2015-01-14
EP1659179A3 (en) 2007-01-17
CY1105685T1 (el) 2010-12-22
EP1584685B1 (en) 2011-04-13
NO328507B1 (no) 2010-03-08
ES2342416T3 (es) 2010-07-06
NO20003958D0 (no) 2000-08-04
EP1584685A3 (en) 2005-12-07
PT1659179E (pt) 2011-09-16
WO1999040188A3 (en) 1999-10-14
EP1659178A3 (en) 2007-01-17
CN1295616A (zh) 2001-05-16
PT1584685E (pt) 2011-06-17
DK1584685T3 (da) 2011-07-11
SI1584685T1 (sl) 2011-07-29
HU228467B1 (en) 2013-03-28
EP1659179A2 (en) 2006-05-24
SI1053325T1 (sl) 2006-06-30
CZ298364B6 (cs) 2007-09-05
NO331719B1 (no) 2012-03-05
EP1584685A2 (en) 2005-10-12
HK1093521A1 (en) 2007-03-02
ES2255248T3 (es) 2006-06-16
DE69929310T2 (de) 2006-08-03
CA2319309C (en) 2010-08-10
DE69942214D1 (de) 2010-05-12
SI1659179T1 (sl) 2011-10-28
US8597656B2 (en) 2013-12-03
CZ20002869A3 (cs) 2001-01-17
IL137442A (en) 2008-04-13
JP4768121B2 (ja) 2011-09-07
HUP0102639A1 (hu) 2001-11-28
US8097257B2 (en) 2012-01-17

Similar Documents

Publication Publication Date Title
HK1033838A1 (en) Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2002024739A3 (en) Spas-1 cancer antigen
WO2000006736A3 (en) Nucleic acids and proteins from group b streptococcus
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
CA2361987A1 (en) Goodpasture antigen binding protein
PL348156A1 (en) Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
HUP0104743A3 (en) Chimeric gene encoding the antigenic determinants of four proteins of l. infantum
EP1220896A4 (en) NEW HUMANE LIPASE PROTEINS, FOR CODING NUCLEIC ACIDS AND THEIR USE
AU2002364696A8 (en) Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof
AU2002259099A1 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
AU2002211715A1 (en) Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
EP1026245A4 (en) ANTIGENIC PROTEIN AND THE NUCLEIC ACID CODING THEREOF
ZA200007318B (en) Particles of HCV envelope proteins: use for vaccination.
SI1141305T1 (sl) Himerni gen, ki kodira antigenske determinante stirih proteinov L. Infantum
AU2001270007A1 (en) Hei-c encoding nucleic acids, polypeptides, antibodies and methods of use thereof
EP1331268A4 (en) NOVEL PROTEINS, GENES ENCODING THESE PROTEINS AND THEIR USE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150202